These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28807142)

  • 21. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder.
    Potkin SG; Ogasa M; Cucchiaro J; Loebel A
    Schizophr Res; 2011 Nov; 132(2-3):101-7. PubMed ID: 21889878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study.
    Higuchi T; Ishigooka J; Iyo M; Hagi K
    Asia Pac Psychiatry; 2020 Mar; 12(1):e12377. PubMed ID: 31837113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
    Citrome L; Du Y; Risinger R; Stankovic S; Claxton A; Zummo J; Bose A; Silverman BL; Ehrich EW
    Int Clin Psychopharmacol; 2016 Mar; 31(2):69-75. PubMed ID: 26517202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies.
    Nasrallah HA; Cucchiaro JB; Mao Y; Pikalov AA; Loebel AD
    CNS Spectr; 2015 Apr; 20(2):140-7. PubMed ID: 24955752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials.
    Marder SR; West B; Lau GS; Pultz JA; Pikalov A; Marcus RN; Gutierrez-Esteinou R; Crandall DT
    J Clin Psychiatry; 2007 May; 68(5):662-8. PubMed ID: 17503974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia.
    Tandon R; Cucchiaro J; Phillips D; Hernandez D; Mao Y; Pikalov A; Loebel A
    J Psychopharmacol; 2016 Jan; 30(1):69-77. PubMed ID: 26645209
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study.
    Mattingly GW; Haddad PM; Tocco M; Xu J; Phillips D; Pikalov A; Loebel A
    BMC Psychiatry; 2020 May; 20(1):199. PubMed ID: 32370778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.
    Stahl SM; Cucchiaro J; Simonelli D; Hsu J; Pikalov A; Loebel A
    J Clin Psychiatry; 2013 May; 74(5):507-15. PubMed ID: 23541189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
    Kittipeerachon M; Chaichan W
    Schizophr Res; 2016 Oct; 176(2-3):231-238. PubMed ID: 27461399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intramuscular aripiprazole in the acute management of psychomotor agitation.
    De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P
    Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p.r.n. medication.
    Chaichan W
    J Psychiatr Pract; 2008 Mar; 14(2):105-13. PubMed ID: 18360196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of lurasidone in schizophrenia: pooled analysis of European results from double-blind, placebo-controlled 6-week studies.
    Calisti F; Cattaneo A; Calabrese M; Mao Y; Tocco M; Pikalov A; Goldman R
    Int Clin Psychopharmacol; 2022 Sep; 37(5):215-222. PubMed ID: 35276716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine.
    Lesem MD; Tran-Johnson TK; Riesenberg RA; Feifel D; Allen MH; Fishman R; Spyker DA; Kehne JH; Cassella JV
    Br J Psychiatry; 2011 Jan; 198(1):51-8. PubMed ID: 21200077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lurasidone for the Treatment of Irritability Associated with Autistic Disorder.
    Loebel A; Brams M; Goldman RS; Silva R; Hernandez D; Deng L; Mankoski R; Findling RL
    J Autism Dev Disord; 2016 Apr; 46(4):1153-63. PubMed ID: 26659550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of HP-3070, an Asenapine Transdermal System, on Symptoms of Hostility in Adults With Schizophrenia: A Post Hoc Analysis of a 6-Week Phase 3 Study.
    Citrome L; Komaroff M; Starling B; Byreddy S; Terahara T; Hasebe M
    J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35687858
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.